

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A61K 38/26, A23L 1/305</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 97/07814</b><br><b>(43) International Publication Date:</b> 6 March 1997 (06.03.97)   |
| <b>(21) International Application Number:</b> PCT/US96/13615<br><b>(22) International Filing Date:</b> 22 August 1996 (22.08.96)<br><b>(30) Priority Data:</b><br>195 30 865.4 22 August 1995 (22.08.95) DE<br><b>(71) Applicant (for all designated States except US):</b> BIONE-<br>BRASKA, INC. [US/US]; 3820 Northwest 46th Street, Lin-<br>coln, NE 68524 (US).<br><b>(71)(72) Applicant and Inventor:</b> NAUCK, Michael, A. [DE/DE];<br>Oberarzt, Medizin. Univ. -Klinik, Ruhr-Universitat<br>Bochum, Knappschaftskrankenhaus, In der Schornau 23-25,<br>D-44892 Bochum (DE).<br><b>(72) Inventor; and</b><br><b>(75) Inventor/Applicant (for US only):</b> WAGNER, Fred, W.<br>[US/US]; Route 1, Box 77B, Walton, NE 68461 (US).<br><b>(74) Agent:</b> BRUESS, Steven, C.; Merchant, Gould, Smith, Edell,<br>Welter & Schmidt, 3100 Norwest Center, 90 South Seventh<br>Street, Minneapolis, MN 55402 (US). |           | <b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU,<br>AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility<br>model), DE, DE (Utility model), DK, DK (Utility model),<br>EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE,<br>HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,<br>LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,<br>RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM,<br>TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS,<br>MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG,<br>KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE,<br>DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE),<br>OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,<br>NE, SN, TD, TG).<br><br><b>Published:</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the<br/>claims and to be republished in the event of the receipt of<br/>amendments.</i> |
| <b>(54) Title:</b> METHOD AND COMPOSITION FOR ENHANCED PARENTERAL NUTRITION<br><br><b>(57) Abstract</b><br><br>A composition and method for improved administration of nutrients is described. The method includes co- or separate administration of a source of nutrients, especially carbohydrates, and insulintropic peptides and derivatives, analogs, fragments and the like. The method and composition provide high carbohydrate nutrition while avoiding hyper- and hypoglycemia and their attendant deleterious effects.   |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                        | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                               | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                               | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                               | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                 | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                 | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                 | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                     | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                            | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                         | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                             | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                               | SN | Senegal                  |
| CN | China                    | LT | Lithuania                             | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                            | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                              | US | United States of America |
| FR | France                   | MR | Mauritania                            | UZ | Uzbekistan               |
| GA | Gabon                    |    |                                       | VN | Viet Nam                 |

**METHOD AND COMPOSITION**  
**FOR ENHANCED PARENTERAL NUTRITION**

**Background of the Invention**

5           Patients suffering from a variety of illnesses often need to take nutrition  
by a route other than through the alimentary canal. Patients requiring surgery,  
patients in comas, patients with digestive tract illness, patients in shock, and patients  
undergoing healing processes often receive parenteral administration of carbohydrates  
along with various combinations of lipids, electrolytes, minerals, vitamins and amino  
10 acids. Typically this administration is accomplished by intravenous injection or  
infusion although subcutaneous, intramuscular, peritoneal or other routes may also be  
used.

          When health care professionals administer parenteral nutrients to  
patients, they take care to avoid blood sugar overload (hyperglycemia). In many  
15 cases, even those involving patients with healthy metabolisms, parenteral nutrition can  
be accomplished and blood sugar levels appropriately maintained through co-  
administration of insulin. This administration sometimes, however, has serious  
drawbacks, since insulin has a short half-life and can cause significant variation in the  
blood sugar levels. Consequently, in serious cases where patients are to receive a  
20 high amount of glucose loading, their blood glucose levels are usually titrated and  
they receive corresponding infusions of insulin to balance the blood glucose level.  
This titration procedure is both time consuming and requires a significant expense  
since the insulin infusion preferably is continuous and has to be controlled by serial  
blood sugar measurement.

25           It is well-established that patients suffering from malnourishment  
benefit greatly from rapid delivery of high amounts of nutrients. Usually, oral routes  
are used for such nutrition so that the health and function of patients' digestive  
processes are maintained. When a non-oral route for nutrition must be used, the risk  
of hyperglycemia and the attendant deleterious effects upon osmolarity, kidney tissue,  
30 retinal tissue, blood vessels, and the cardiovascular system are great even if insulin  
co-administration is practiced. Consequently, the traditional nutrition therapies,  
which often do not use insulin, call for very low rates of nutrient parenteral

administration. When a typical patient receives such parenteral nutrition, the rate of administration is maintained at a low value so that the blood sugar (glucose) level does not exceed the normal physiological range of approximately 60 to 150 mg per dl. These low rates of administration provide an appropriate safety factor to avoid  
5 hyperglycemia. Usually, the rates range from 50 to 150 ml per hour of a 5 to 40 wt/wt. % glucose solution.

Nevertheless, nutrition is a fundamental requirement to enable patient healing and sustenance. If patients cannot receive adequate nutrition, as many times occurs with traditional parenteral nutrition, healing takes longer and ancillary  
10 problems associated with the patient's primary malcondition often occur. Therefore, there often is a need to deliver parenteral nutrition to a patient at as high a rate as possible while avoiding the deleterious effect of hyperglycemia and avoiding the need for repetitive or continuous insulin administration and titration.

### 15 Summary of the Invention

These and other objects are achieved by the invention which is directed to a composition and method for maximal parenteral nutrition substantially without acute or chronic hyperglycemia. The use of the composition in the method of the invention enables delivery of requisite nutrients to satisfy the caloric demand of a  
20 patient's healing tissues while at the same time maintaining an appropriate blood glucose level.

The composition of the invention includes a source of nutrients and an insulinotropic peptide. The source of nutrients directly or indirectly provides carbohydrate after administered. Preferably the source of nutrients includes hexoses,  
25 pentoses, alcohols thereof and the like, especially those that are highly soluble in aqueous media. Examples include glucose, fructose, galactose, sorbitol, mannitol, zylitol or any combination thereof. Optionally included can be amino acids, electrolytes, lipids, free fatty acids, monoglycerides, diglycerides, triglycerides, glycerol, salts and minerals. The insulinotropic peptide includes gastric inhibitory  
30 peptide and its derivatives, glucagon-like peptides such as GLP-1 (1-37) and GLP-1 (7-36), and their derivatives having insulinotropic activity including functional group modifications such as GLP-1 (1-37) amide, GLP-1 (7-36) amide and GLP-1 (7-36)

methylester, their peptide sequence fragments such as GLP-1 (7-34), GLP-1 (7-37), GLP-1 (7-36), GLP-1 (7-35), their peptide sequence substitutes such as GLP-1 (7-34) Ala Phe Ala, their peptide sequence deletions such as des (Lys) GLP-1 (7-37) amide, their peptide sequence analogs including those with non-natural amino acid residues, as well as their small organic molecule mimics. The insulinotropic peptide may be a pure single compound, a semi-pure single compound or any mixture of compounds such a mixture of GLP-1 and GIP. The source of nutrients and insulinotropic peptide can be combined in a single aqueous medium or can be contained in separate aqueous media, preferably as a kit. Alternatively, the insulinotropic peptide can be separately formulated in tablet or sustained release matrix form for delivery by a buccal, subcutaneous or other absorption route. The concentrations of nutrients and insulinotropic peptides in the composition are described below.

The method of the invention is accomplished by parenteral mixtures of peptides administration of the source of nutrients and the insulinotropic peptide. The administration can be accomplished by prior combination of the nutrient source and peptide, by their co-administration from separate sources, by their separate but concomitant administration or by their separate and sequential administration with the insulinotropic peptide being administered first. Individual peptide compounds as well as mixtures of peptide compounds as described above can be administered as the insulinotropic peptide. The route of administration for the nutrients can be any parenteral route such as intraperitoneal or intravenous while the route for the insulinotropic peptide can be the same as or different from the route for the nutrients. The concentration of the insulinotropic peptide used may be any that will deliver and/or maintain normal blood glucose levels in patients who are receiving the source of nutrients according to the invention. The concentrations of nutrients in the nutrient source are at least the same as that typically used for parenteral feeding and the rate of administration is at least the same but is preferably higher than typically prescribed such as preferably a rate providing up to 1000 g of glucose or its equivalent per patient per day. The appropriate dosage of insulinotropic peptide is determined by its sigmoidal dose-response curve relative to the blood glucose level. Consequently, the administration of insulinotropic peptide follows a threshold/increasing level/plateau regimen and is balanced with the rate of administration of the nutrient source so that a

normal glucose blood level is achieved or maintained while delivering the nutrient source at an administration rate that would cause the blood glucose level to exceed its normal range if the insulintropic peptide were not also present. Preferably, the carbohydrate concentration in the nutrient source is in the range of 2% to 50% glucose or its equivalent by weight relative to the total weight of the source. Preferably, the rate of administration of insulintropic peptide will be calculated to provide and/or maintain at least intermittent peptide blood levels of from 0.1 pmol to 0.1 mmol per liter of plasma.

### Detailed Description of the Invention

The present invention is directed to a composition and a method for of parenteral nutrition of a patient, especially carbohydrate nutrition, without causing deleterious fluctuations in the patient's blood glucose level. Substantially more rapid delivery of nutrients is achieved by the invention relative to traditional parenteral nutrition so that the calorie demand of the patient's healing cells is almost always met and blood sugar level of the patient does not substantially vary. These unexpected and important medical effects are achieved through the use of a composition of insulintropic peptides and nutrients such as carbohydrates, amino acids, lipids, monoglycerides, diglycerides, triglycerides, fatty acids, salts, electrolytes and/or minerals.

Although insulintropic peptides such as GLP-1, GIP and at least some of their fragments, analogs, derivatives and other similar compounds have been known for some time, their use has been directed solely to patients with diabetes. Their application and effect in non-diabetic persons has not been suggested. Indeed, the suggested use of insulintropic peptides for treatment of diabetic patients indicates that the insulintropic peptides would have an insulin stimulating effect at these patients' ordinary glucose blood levels. Based upon this suggestion, it would seem that the difficulties occurring with the nutritional administration of insulin would also occur with nutritional use of insulintropic peptide. Such use would require blood glucose level titration and continuous monitoring of the peptide delivery.

According to the invention, it has been surprisingly found that exogenous administered insulintropic peptides do not substantially heighten insulin

release in a normal patient when he has a normal (non-diabetic) blood glucose level. Furthermore, it has been found according to the invention that when glucose is administered to a normal (non-diabetic) patient by a non-alimentary route, the normal regulatory pathway and mechanism for endogenous insulintropic peptide production, release, receptor interaction and/or past receptor events either do not occur or are shunted. It has been found that when such a non-diabetic patient undergoes a change in his blood glucose level so as to exceed his normal value, such as by non-alimentary administration of glucose, an insulin stimulatory effect caused by exogenously administered insulintropic peptide occurs so as to lower the blood glucose level to a normal value. According to the invention, these discoveries have resulted in a method of high and rapid nutrition that avoids hyperglycemia while also avoiding the dangers of hypoglycemia owing to too much insulin and too little blood glucose.

The insulintropic peptides are used in combination with the nutritional media to provide parenteral nutrition according to the invention. Stabilization of blood glucose levels is achieved readily and significantly with the exogenous parenteral delivery of the insulintropic peptides. Especially, insulin secretion during parenteral administration of nutrients is highly regulated in this fashion so that increases in blood glucose are significantly less than would be seen without the presence of the insulintropic peptide. Because a non-diabetic patient has been found to be refractory to the insulintropic peptide until the glucose level exceeds the patient's normal fasting blood glucose level, and because it has been found that blood insulin levels continue to rise with increasing blood glucose levels and blood insulintropic peptide levels up to a plateau, and because the blood insulin levels continue to rise with increasing blood glucose levels even though blood insulintropic peptide levels are held at the plateau level, the amount of insulintropic peptide to be administered preferably can be standardized irrespective of the amount of glucose to be delivered. Therefore, relative to a nutritional regimen without the insulintropic peptides, more glucose or its equivalent can be delivered over a shorter time to a patient and the patient's calorie deficit can be more rapidly and satisfactorily fulfilled by practice of the invention. These results are obtained according to the invention without any corresponding side effects from hyper- or hypoglycemia.

According to the invention, the composition to be administered can include carbohydrates alone, such as, hexoses or pentoses, specific examples of which are glucose (dextrose), fructose, galactose, xylitol, mannitol and sorbitol and the like. Alternatively, the composition can include an indirect source of glucose such as lipids, fatty acids, diglycerides, monoglycerides, glycerol and/or amino acids which would be converted to glucose through gluconeogenesis. Electrolytes and minerals such as sodium chloride, potassium chloride, magnesium sulfate, potassium gluconate, sodium acetate, potassium biphosphate, potassium acetate, multiple vitamins and trace elements such as chromium may also be present. Preferably, the composition includes a soluble carbohydrate source such as glucose or one which can be readily converted by the body to glucose. Preferably, other components included in the composition of the invention include a carrier substance such as human serum albumin as well as electrolytes such as sodium chloride, potassium chloride, magnesium chloride, buffers, stabilizers, and preservatives.

The composition can be delivered by injection or infusion as well as by intramuscular, subcutaneous, intravenous, intrarticular, intraperitoneal, buccal (peptides only), nasal membrane (peptides only) and other non-alimentary routes. The nutrients and insulinotropic peptides can be delivered by the same or different routes. It is especially advantageous to deliver the composition by an intravenous route or to deliver the nutrients by an intravenous route and the insulinotropic peptides by a buccal route.

The concentrations of nutrients present in the composition and their rate of delivery are designed to deliver more calories over a 24-hour period than possible with glucose solutions alone. The typical, standard dextrose or glucose solution for use in well-known i.v. feeding is a 5-40 wt/wt% aqueous glucose solution containing some electrolytes. This standard solution is usually delivered at a rate of 50-100 ml per hour so as to maintain a normal blood glucose level of between 100 and 150 milligrams per deciliter. Although this same blood glucose level is maintained through the method of invention, it is now possible to use more concentrated solutions of nutrients and deliver them at faster rates. In particular, the composition of the invention may contain as much as about 50% by weight glucose or its equivalent. The rate of delivery may also be increased so that a 2%, 5%, 10%,



15%, 25% , 40% or 50% by weight solution of glucose or its equivalent can be delivered to provide up to 1000 gm. of glucose or glucose equivalent per patient per day. Care needs to be taken, of course, so that tissue shock at the site of injection does not occur from the delivery of the highly concentrated solutions.

5           The blood glucose level is maintained at the normal values according to the invention through the co-administration of the insulintropic peptides. These peptides may be administered as individual pure or semi-pure compounds or in mixture with each other. Consequently, when the singular and plural terms "insulintropic peptide or insulintropic peptides" are used in this application, they  
10 are meant to cover all degrees of purity of the peptide as well as the individual forms of the peptides and their mixtures in any combination. Typically, the peptide is delivered so as to provide blood concentrations on the order of picomoles to micromoles per L quantities. The insulintropic peptides may be combined with the nutrients immediately before administration, may be co-administered with the  
15 nutrients by use of a separate vessel for the peptides which leads into a common administration line or separate lines to the patient, or may be combined with the nutrients upon manufacture and stored under appropriate conditions to preserve peptide integrity. Alternatively, the insulintropic peptides can be formulated into pharmaceutically acceptable absorption tabs or tablets, or sustained release matrices  
20 such as in a polylactide-glycolide matrix. These solid forms are designed for short to medium term release and absorption of peptides and are known in the art such as, WO/96/07398, DE 3822459, and "Drug Development and Industrial Pharmacy", 21(17), 2013-2019 (1995), the disclosures of which are incorporated herein by reference.

25           The particular regimen and amount of insulintropic peptide or peptides administered to an individual patient will depend upon the judgment of the attending physician and the patient's particular condition. As a guideline, if glucose or its nutritional equivalent is to be delivered at higher rates so as to provide up to about 1000 g of glucose per day to the patient, a corresponding larger amount of one  
30 or more insulintropic peptides would be delivered up to a plateau level of about 3 pmol per kg patient weight per minute. This sigmoidal dose-response curve for the insulintropic peptide has a threshold level followed by the increasing dosage curve

up to a plateau of the foregoing level. The dose-response curve is dependent upon the amount of glucose being administered and upon the blood glucose level of the patient. The patient will be refractory to the insulinotropic peptide effect when his blood glucose level is within his normal range. The sigmoidal dose-response occurs when the blood glucose level exceeds that normal range for the non-diabetic patient. At and above that plateau level, insulin stimulation continues and results in increased insulin levels in the blood but the increase follows the level of blood glucose and not the insulinotropic peptide level.

Preferably, the insulinotropic peptides are maintained in a separate, sterile, solid state until shortly before their use. To be used, the solid insulinotropic peptides are preferably combined with sterile buffered aqueous medium to form concentrations of the insulinotropic peptide in the range of nmol to mmol per L levels. Alternatively, the peptides may be combined with a sustained release matrix such as polylactides, polyglycolides, polycaprolactones, hydrogels, microporous polyurethanes, polyvinylidene acetate and the like which are known to provide sustained release of peptides. These formulations can be manipulated to provide short or medium term release of the peptides. See for example U.S. Patent No. 5,364,838, U.S. Patent No. 5,383,848, WO/96/07398, DE 3822459, U.S. Patent No. 5,487,898, "Drug Development and Industrial Pharmacy", 21 (17), 2013-2019 (1995), "Diabetes Care", Vol. 19(8), 843-848 (1996), "Journal of Medicinal Chemistry", (Vol. 38, pg. 4257-4269) and WO/93/18785, the disclosures of which are incorporated herein by reference.

The formulas for the insulinotropic peptides used according to the invention include all known forms of GLP-1 and GIP (the glucagon-like peptide -1 and the gastric inhibitory peptide) and their derivatives. In particular, GLP-1 can be used according to the invention as well as its derivatives including peptide fragments such as GLP-1 (1-36), GLP-1 (1-37), GLP-1 (7-36), GLP-1 (7-37), GLP-1 (7-34), GLP-1 (7-35), similar versions containing substitutions of amino acids such as GLP-1 (7-34) Ala Phe Ala, deletion sequences such as des (Lys) GLP-1 (7-36) amide, analogs with non-natural amino acid residues (e.g., taurine residue, beta and gamma amino acid residues and D-amino acid residues), C-terminal functional group modifications such as amides, esters, and C-terminal ketone modifications and N-

terminal functional group modifications such as acylated amines, Schiff bases and the like as well as exendin, glicentin, amylin antagonists and other derivatives such as are described in EP 512042 (Derwent 91-252609/34), WO9325579A1 (Derwent 94-007457/01), WO9318786 (Derwent 93-3220451/40) WO9011296 (Derwent 90-320226/42), U.S. Patent No. 5,545,618, JP63159323 (Derwent 88-224231/32), U.S. Patent No. 5,118,666, U.S. Patent No. 5,120,712, U.S. Patent No. 5,512,549, WO9606628, and EP658568, the disclosures of which are incorporated herein by reference. Also included are traditional small organic molecule mimics of the insulinotropic peptides which fit the insulinotropin receptor sites.

These insulinotropic peptides are known and described in the literature. They can be obtained from natural sources as well as by manufacture using recombinant technology or automated and classical synthesis techniques. In particular, reference is made to PCT patent application no. 94/08125 which describes the synthesis of GLP-1 (7-36) amide by a recombinant biotechnology technique. The purities of the insulinotropic peptides may range from semi-pure to highly pure. Their activities in these various states of purity for example can be obtained through titration according to an assay for quantitative insulin release from isolated B-cells of rat pancreas in a saline glucose solution as is taught by Schmidt in Diabetologia (1985) 28:704-707. The titration will provide an activity unit quotient which would be used as a basis to determine the equivalent amount of semi-pure insulinotropic peptide to be administered relative to the amount of pure insulinotropic peptide.

Stock solutions of the insulinotropic peptide which are useful for practice of the invention include an isotonic salt solution such as 0.9% sodium chloride containing from 0.1 to 5% (volume/volume) of a carrier substance such as human serum albumin along with from 1 nmol to 1 mmol per liter of the insulinotropic peptide such as GLP-1 (7-36) amide. This stock solution can be diluted by a factor of 20 for use in infusion with the nutrient solution. Suitable infusion rates for the insulinotropic peptides will range from 0.01 to 50 pmol of peptide per kg of body weight of patient per minute and preferably in the range of 0.2 to 2.5 pmol of peptide per kg of body weight of patient per minute. The administration rate of glucose co-administered with the insulinotropic peptide, especially preferably, may

range up to 1000 g of glucose per day or its equivalent, and/or from about 10 to about 800 g of an amino acid mixture per day.

Patients who are especially suited for treatment according to the present invention include patients with a disturbed glucose metabolism such as insulin resistance but no overt diabetes, as well as patients who for any reason cannot receive nutrition through the alimentary canal. Such patients include surgery patients, comatose patients, patients in shock, patients with gastrointestinal disease, patients with digestive hormone disease, and the like. In particular, obese patients, atherosclerotic patients, vascular disease patients, patients with gestational diabetes, patients with liver disease such as liver cirrhosis, patients with acromegaly, patients with glucocorticoid excess such as cortisol treatment or Cushing's disease, patients with activated counterregulatory hormones such as would occur after trauma, accidents and surgery and the like, patients with hypertriglyceridemia and patients with chronic pancreatitis can be readily and suitably nourished according to the invention without subjecting the patient to hypo- or hyperglycemia. In particular, the administration to such a patient aims to provide a therapy to as rapidly as possible deliver the nutritional and caloric requirements to the patient while maintaining his plasma glucose below the so-called renal threshold of about 160 to 180 milligrams per deciliter of glucose in the blood. Although normal patients not having glucose levels just below the renal threshold can also be treated according to the invention as described above, patients with disturbed glucose metabolism such as hyperglycemic patients whose plasma glucose level is just above the renal threshold also find the therapy suitable for their condition. In particular, such patients who have a degree of hyperglycemia below the renal threshold at intermittent intervals can receive a combination treatment of nutrients plus insulinotropic peptides according to any of the following regimens. Normal patients not suffering from such hyperglycemia can also be treated according to any of the following regimens.

#### **Regimen A**

The patient will receive a fixed i.v. dose of the insulinotropic peptide such as GLP-1 in an amount between 1 to 2 pmol per kilogram of patient weight per minute. The co-administered i.v. nutrients are titrated to the patient to reach a steady state plasma glucose level of approximately 150 milligrams per deciliter or just below

the patient's renal threshold. The insulinotropic peptide and the nutrient composition are separately administered through a common i.v. line.

#### Regimen B

5 The patient receives a fixed amount of i.v. nutrients according to the patient's nutritional requirements and the insulinotropic peptide such as GLP-1 (7-37) is titrated starting at about 0.4 pmol per kg patient weight per minute to up to an infusion rate just below a maximum of approximately 3 pmol per kg patient weight per minute.

#### Regimen C

10 The patient receives a fixed amount of nutrients in a nutritional composition (such as up to 1000 g of glucose per day) in combination with a fixed amount of insulinotropic peptide (such as GLP-1 (7-34) at an infusion rate of 2 pmol per kg patient weight per min.). These are administered through separate or common i.v. infusion lines.

15 To titrate or otherwise follow the progress of the patient during the initial stages and periodically during the treatment using the composition of the invention, the patient can receive the following workups. The patient's blood sugar will be determined at approximately every two hours in the first day and approximately every six hours thereafter. The patient will have insulin and glucagon  
20 blood levels titrated before and under treatment to optionally determine the blood insulin and glucagon levels in the patient. The patient optionally may receive indirect calorimetry to determine the patient's glucose oxidation-rate and energy expenditure in order to determine the patient's nutritional need and whether his caloric level needs to be increased, decreased or maintained.

25 The invention has been fully characterized according to the foregoing description. The following examples and protocols provide detailed embodiments of some aspects of the invention. The invention however is not limited to these embodiments and aspects.

### **Protocol**

#### **Provision of Incretin Stimulation Of The Insulin Secretion Through Exogenous GLP-1 (7-36) Amide During Parenteral Nourishment.**

5 The goal of this protocol is to ameliorate the problems associated with:  
parenteral nourishment. It is very often not possible to infuse a desired amount of  
glucose even to people with healthy metabolism without provoking hyperglycemia (1).  
Therefore it is necessary even with non-diabetics to add insulin. This results in many  
time- and money-consuming control tests and limits glucose uptake.

10 A possible reason for the insufficient endogenous insulin secretion is  
the lack of the incretin stimulation. Incretin stimulates the secretion of insulin  
through the effect of intestinal hormones released after oral glucose intake. This  
stimulation is much better than the insulin increase caused by increasing plasma  
concentration of such substrates as glucose and amino acids alone. Two of these  
15 incretin hormones from the intestines, GLP-1 (7-37) (i.e., the acid) and GLP-1(7-36)  
amide, have a very strong glucose-dependent insulintropic and glucagonostatic  
effect. High doses of such incretins do not lead to hypoglycemia by healthy people,  
because those incretins have been found in animal tests to have hardly any influence  
on insulin secretion at normal (sober) plasma glucose values.

20 Insulin secretion during parenteral nourishment in the presence of  
GLP-1(7-36 amide) can be controlled such that the plasma glucose increase will be  
less than without GLP-1. Therefore more glucose can be delivered over a 24 hour  
period than otherwise. The calorie deficit seen with parenterally nourished patients  
can be better satisfied.

### **PART A**

25 The study is conducted as follows. Patients include both sexes between  
the ages 18 and 75 who are dependent on parenteral nourishment. Patients are  
excluded if they suffer from acute diseases (i.e., fever), and insulin-dependent  
diabetes and restricted liver and kidney functions (kreatinin > 1.2 mg/dl), pregnancy,  
anemia (hemoglobin < 10 g/dl) and treatments with mechanical breathing support and  
30 catecholamines. Every patient participates in one study day.

To begin the study, a constant central venous infusion of glucose/amino  
acid mixture (Aminomix, Fresenius AG) without the infusion of a triglycerid

suspension should be used to continue the parenteral nourishment already in progress. The dose corresponds to the clinically determined calorie demand of the patient. The plasma concentrations of glucose, free fatty acids, triglycerides, amino acids, insulin, C-peptide and GLP-1 (7-36 amide) levels naturally present should be determined every hour for the next 4 hours in the "steady state". If the glucose concentration in this "steady state" is above 150 mg/dl, a sterile and pyrogene free solution of GLP-1 (7-36 amide) (1.2 pmol/kg/min) should be infused for the next 4 hours and all the above values should be measured again in 1 hour intervals. This dose corresponds to the normal "substitution dose" for the incretin hormone GLP-1 (7-36) amide (0.3 - 0.4 pmol/kg/min) (2) and the necessary pharmacological dose for type 2 diabetics of 1.2 pmol/kg/min (7,8). The treatment is expected to stimulate the insulin secretion and subsequently normalize the plasma glucose. Supplementing this study are indirect calorimetry measurements (Deltratrak, Datex, Finland). Therefore 20 min measurement periods are necessary at the start, after 4 hours and at the end of the GLP-1 (7-36) amide infusion period of 8 hours. It is also possible to determine changes in the substrate utilization (glucose and lipid oxidation, energy consumption) from these measurements.

#### **PART B**

Every patient participates in three study days.

To begin the study, a constant central venous infusion of glucose/amino acid mixture (Aminomix, Fresenius AG) without the infusion of a triglycerid suspension should be used to continue the parenteral nourishment already in progress. Placebo, GLP-1 (7-36) amide (0.6 pmol/kg/min) with possible changes up to 1.2 pmol/kg/min according to results of study A and insulin (2U per hr.) should be infused in a random day order. Plasma glucose concentrations should be determined every half hour for the next 6 hours. The glucose infusion should be increased to reach a "steady state" glucose concentration of 150 mg/dl very fast and kept at this level. To supplement this study glucose, free fatty acids, triglycerides, amino acids, insulin, C-peptide and GLP-1 (7-36 amide) should be measured every hour. Indirect calorimetry is preformed at the start and end of the 6 hour period.

For taking blood samples it is necessary to place one peripheral vein catheter besides the central vein catheter. Physiological NaCl is slowly infused to keep the vein "open".

5 GLP-1 (7-36) amide should be received as a GMP product and should be stored at -30°C as a sterile stock solution (in 0.9% NaCl with 1% human serum albumin). Samples are taken before infusion, sterile-filtered and tested for bacteria growth and endotoxins with the limulus assay.

Blood samples should be taken at the following time points: 0, 60, 120, 180, 240, 300, 360, 420, 480 (study A) and: 0, 60, 120, 180, 240, 300, 360, 420, 10 480, 540, 660 and 720 (study B).

The statistical analysis can be done with repeated measurement analysis of variance supplemented by one-way ANOVA and t-tests.

#### Example

15 A 60-year old patient was fed parenterally because of inflammatory bowel disease. He weighed 75 kg. The parenteral nourishment was delivered by a infusomate through a central vein catheter and consisted of 1.5 liter of a 40% glucose solution to deliver approximately 600 g of glucose in 24 hrs and 1 liter of a 10% commercial amino acid mixture. The blood sugar values achieved without GLP-1 (7- 20 36) amide were between 160 and 190 mg/dl. Then GLP-1 (7-36) amide was administered and the blood glucose value was decreased to about 100 mg/dl even though the patient's high rate of glucose administration was continued.

GLP-1 or GIP may be used as a companion medication. The insulintropic peptide medicament was prepared by a 20:1 dilution of the following 25 stock solution of peptide using normal saline. A stock solution of GLP-1, containing 50 µg/ml and dissolved in 0.9% NaCl with the addition of human serum albumin (end conc. 1% vol/vol) was prepared. The solution was tested for bacterial contamination and pyrogenes and can be stored for 3 months (frozen at -30 C).



**WE CLAIM:**

Claim 1. A method for non-alimentary nutrition comprising administering to a patient in need of nutrition a pharmaceutical composition comprising a source of nutrients and one or more insulintropic peptides.

Claim 2. A method according to claim 1 wherein the source of nutrients is a source of carbohydrates.

Claim 3. A method according to claim 2 wherein the source of carbohydrate is a hexose, pentose, hexose alcohol, pentose alcohol, or any combination thereof.

Claim 4. A method according to claim 3 wherein the source of carbohydrate is glucose, fructose, galactose, zylitol, mannitol, sorbitol, or any combination thereof.

Claim 5. A method according to claim 1 wherein the source of nutrients is one or more assimilable amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol.

Claim 6. A method according to claim 2 wherein the administration of the source of carbohydrate to the patient produces a blood glucose level in the patient of no more than from about 80 to 180 mg glucose per deciliter of blood and the rate of administration of the source of carbohydrate is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.

Claim 7. A method according to claim 1 wherein the administration of the insulintropic peptide or peptides produces a blood level of the peptide or peptides in the range of 1 pmol per L to 1 mmol per L of blood plasma.

Claim 8. A method according to claim 1 wherein the insulinotropic peptide is GLP-1, GIP, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketone modifications thereof, the N-terminus modifications thereof or any mixture thereof.

Claim 9. A method according to claim 2 wherein the pharmaceutical composition comprises the source of carbohydrate in a first aqueous medium and one or more insulinotropic peptides in a second aqueous medium or in a pharmaceutically acceptable solid or gel tab or sustained release matrix.

Claim 10. A pharmaceutical composition comprising a source of nutrients and one or more insulinotropic peptides in combined or separate form.

Claim 11. A pharmaceutical composition according to claim 10 wherein the source of nutrients is a source of carbohydrates.

Claim 12. A pharmaceutical composition according to claim 11 wherein the source of carbohydrate is present at a concentration of about a 2% to about a 50% by weight of glucose or its equivalent per L.

Claim 13. A composition according to claim 10 wherein the insulinotropic peptide or peptides are present at a concentration of about 1 nmol per L to about 1 mmol per L.

Claim 14. A pharmaceutical composition comprising a kit containing a first aqueous mixture of a source of nutrients contained in a form for parenteral administration and a second aqueous mixture or solid or gel tab or sustained release

matrix of one or more insulintropic peptides contained in a form for parenteral administration.

4  
5. Claim 15. Use of a pharmaceutical composition according to claim 10 for nutrition of a patient.

10 Claim 16. Manufacture of a pharmaceutical composition for use in nutrition of a patient comprising preparation of a pharmaceutically acceptable formulation of a source of nutrients and preparation of a pharmaceutically acceptable formulation of one or more insulintropic peptides.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/13615

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K38/26 A23L1/305

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| X        | DIABETES,<br>vol. 34, no. 11, November 1985,<br>pages 1108-1112, XP002023281<br>A.R.BAER ET AL.: "Effects of Gastric<br>Inhibitory Polypeptide in the Response to<br>Prolonged Parenteral or Enteral<br>Alimentation in Rats"<br>see page 1109, column 1, paragraph 2<br>---              | 1-5,<br>8-13, 16      |
| X        | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY,<br>vol. 20, no. 3, - April 1985<br>pages 321-324, XP002023282<br>P.F.AMLAND ET AL.: "Effects of Atropine<br>on GIP-Induced Insulin and Pancreatic<br>Polypeptide Release in Man"<br>see page 321, column 2, paragraph 3-4<br>---<br>-/--<br>--- | 1-4,<br>8-14, 16      |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

22 January 1997

Date of mailing of the international search report

31. 01. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Van Moer, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/13615

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|----------|--|-----------------------|
| X,P      | DIABETES CARE,<br>vol. 19, no. 8, August 1996,<br>pages 843-848, XP002023283<br>M.K.GUTNIAK ET AL.: "Potential<br>Therapeutic Levels of Glucagon-like<br>Peptide I Achieved in Humans by a Buccal<br>Tablet"<br>cited in the application<br>see page 844, column 2, paragraph 1<br>--- | 1-4,<br>8-14,16       |
| X        | WO,A,93 18785 (NOVO NORDISK) 30 September<br>1993<br>cited in the application<br>see page 8, line 21-23; claims<br>---   | 1,2,5,<br>8-13,16     |
| X        | WO,A,93 11799 (PFIZER) 24 June 1993<br><br>see claims<br>---   | 1,5,<br>8-13,16       |
| X        | EP,A,0 619 322 (PFIZER) 12 October 1994<br><br>see claims 1,3,7<br>---   | 1,5,<br>8-13,16       |
| A        | PATENT ABSTRACTS OF JAPAN<br>vol. 017, no. 647 (C-1135), 2 December<br>1993<br>& JP,A,05 207846 (SNOW BRAND MILK PROD CO<br>LTD), 20 August 1993,<br>see abstract<br>---   | 1                     |
| E        | DATABASE WPI<br>Section Ch, Week 9651<br>Derwent Publications Ltd., London, GB;<br>Class B04, AN 96-514913<br>XP002023284<br>& JP,A,08 268 908 (GREEN CROSS CORP) , 15<br>October 1996<br>see abstract<br>---  | 1-5,<br>8-13,16       |
| P,A      | US,A,5 487 898 (MOU-YING F.LU ET AL.) 30<br>January 1996<br>cited in the application<br>see claims 1,6,11<br>-----   |                       |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/13615

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO-A-9318785                              | 30-09-93            | AU-A- 3888793              | 21-10-93            |
|   |                     | EP-A- 0631504              | 04-01-95            |
|   |                     | JP-T- 7504669              | 25-05-95            |
| -----                                     |                     |                            |                     |
| WO-A-9311799                              | 24-06-93            | AU-A- 3058392              | 19-07-93            |
|   |                     | CA-A- 2125400              | 24-06-93            |
|   |                     | EP-A- 0617626              | 05-10-94            |
|   |                     | FI-A- 942938               | 17-06-94            |
|   |                     | HU-A- 69785                | 28-09-95            |
|   |                     | JP-T- 6510796              | 01-12-94            |
|   |                     | NO-A- 942323               | 17-06-94            |
|   |                     | PT-A- 101135               | 31-03-94            |
|   |                     | ZA-A- 9209761              | 17-06-94            |
| -----                                     |                     |                            |                     |
| EP-A-619322                               | 12-10-94            | AU-A- 5501694              | 13-10-94            |
|   |                     | BR-A- 9401185              | 18-10-94            |
|   |                     | CA-A- 2116478              | 08-10-94            |
|   |                     | CN-A- 1106698              | 16-08-95            |
|   |                     | CZ-A- 9400275              | 17-05-95            |
|   |                     | HU-A- 68525                | 28-06-95            |
|   |                     | JP-A- 7002695              | 06-01-95            |
|   |                     | NO-A- 940436               | 10-10-94            |
|   |                     | NZ-A- 250844               | 26-03-96            |
|   |                     | ZA-A- 9400878              | 10-08-95            |
| -----                                     |                     |                            |                     |
| US-A-5487898                              | 30-01-96            | US-A- 5284657              | 08-02-94            |
|   |                     | AU-B- 669856               | 27-06-96            |
|   |                     | AU-A- 2519392              | 16-03-93            |
|   |                     | EP-A- 0601053              | 15-06-94            |
|   |                     | JP-T- 6510046              | 10-11-94            |
|   |                     | WO-A- 9303751              | 04-03-93            |
| -----                                     |                     |                            |                     |